Ram Mukunda - 31 Mar 2025 Form 5 Insider Report for IGC Pharma, Inc. (IGC)

Role
CEO, Director
Signature
/s/ Ram Mukunda
Issuer symbol
IGC
Transactions as of
31 Mar 2025
Transactions value $
$0
Form type
5
Filing time
15 May 2025, 16:10:28 UTC
Previous filing
18 Mar 2024
Next filing
20 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mukunda Ram CEO, Director 10224 FALLS ROAD, POTOMAC /s/ Ram Mukunda 15 May 2025 0001047575

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGC Common Stock Options Exercise $0 +233,333 +6.6% $0 3,759,345 31 Mar 2025 Direct F1
transaction IGC Common Stock Options Exercise $0 +333,333 +8.9% $0 4,092,678 31 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGC Restricted Stock Units Options Exercise $0 -233,333 -100% $0 0 31 Mar 2025 Common Stock 233,333 Direct F1, F3
transaction IGC Restricted Stock Units Options Exercise $0 -333,333 -50% $0 333,333 31 Mar 2025 Common Stock 333,333 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 25, 2022, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2023.
F2 On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2024.
F3 Each restricted stock unit represents a right to receive one share of IGC common stock.